Hologic, Inc. $HOLX Shares Acquired by GW&K Investment Management LLC

GW&K Investment Management LLC boosted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 32.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 725,249 shares of the medical equipment provider’s stock after purchasing an additional 179,319 shares during the quarter. GW&K Investment Management LLC’s holdings in Hologic were worth $48,948,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Winnow Wealth LLC purchased a new stake in shares of Hologic in the third quarter valued at about $26,000. Root Financial Partners LLC purchased a new stake in Hologic during the 3rd quarter valued at approximately $27,000. SJS Investment Consulting Inc. lifted its position in Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 362 shares during the period. Loomis Sayles & Co. L P acquired a new stake in Hologic during the 2nd quarter worth approximately $33,000. Finally, Smartleaf Asset Management LLC grew its stake in shares of Hologic by 168.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 310 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Performance

Shares of HOLX opened at $75.67 on Thursday. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $75.69. The company has a 50-day simple moving average of $75.00 and a 200-day simple moving average of $72.29. The company has a market capitalization of $16.89 billion, a PE ratio of 31.53, a P/E/G ratio of 2.25 and a beta of 0.73.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a return on equity of 19.58% and a net margin of 13.18%.The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the prior year, the firm posted $0.87 EPS. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. Equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Morgan Stanley upped their price target on Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. BNP Paribas Exane downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a report on Friday, November 21st. Evercore lowered shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their price target for the stock from $79.00 to $78.00 in a research note on Monday, January 5th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Two research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $78.42.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.